Axon Enterprise, Inc $AXON is Towarzystwo Funduszy Inwestycyjnych PZU SA’s 7th Largest Position

Towarzystwo Funduszy Inwestycyjnych PZU SA raised its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 46.4% in the 4th quarter, Holdings Channel reports. The fund owned 24,365 shares of the biotechnology company’s stock after acquiring an additional 7,726 shares during the quarter. Axon Enterprise accounts for approximately 3.5% of Towarzystwo Funduszy Inwestycyjnych PZU SA’s portfolio, making the stock its 7th biggest position. Towarzystwo Funduszy Inwestycyjnych PZU SA’s holdings in Axon Enterprise were worth $13,838,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV purchased a new stake in Axon Enterprise during the 4th quarter valued at approximately $28,000. New Millennium Group LLC purchased a new stake in Axon Enterprise during the 3rd quarter valued at approximately $29,000. Sound Income Strategies LLC raised its stake in Axon Enterprise by 550.0% during the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 44 shares during the last quarter. Camelot Portfolios LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at approximately $30,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at approximately $34,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Citigroup reaffirmed a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. UBS Group dropped their target price on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Needham & Company LLC dropped their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Royal Bank Of Canada dropped their target price on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Finally, Robert W. Baird set a $800.00 target price on Axon Enterprise in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $441.73 on Monday. The business’s fifty day moving average price is $410.34 and its two-hundred day moving average price is $488.94. The stock has a market cap of $35.60 billion, a PE ratio of 177.40, a price-to-earnings-growth ratio of 8.03 and a beta of 1.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.Axon Enterprise’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.47 EPS. On average, analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Insider Activity

In other Axon Enterprise news, insider Elizabeth Reid Coughlin sold 1,554 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the sale, the insider owned 34,024 shares in the company, valued at approximately $16,501,640. This represents a 4.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Cameron Brooks sold 1,242 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the sale, the executive owned 49,710 shares in the company, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 39,344 shares of company stock worth $19,267,315 in the last quarter. 4.20% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.